Organogenesis (NASDAQ:ORGO) Director Sells $534,000.00 in Stock

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf sold 100,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $5.34, for a total value of $534,000.00. Following the sale, the director owned 2,965,591 shares in the company, valued at approximately $15,836,255.94. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Organogenesis Stock Performance

Organogenesis stock traded up $0.14 during mid-day trading on Wednesday, reaching $5.42. 1,027,809 shares of the stock traded hands, compared to its average volume of 1,443,026. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. Organogenesis has a 12-month low of $2.61 and a 12-month high of $7.08. The stock has a market capitalization of $687.85 million, a PE ratio of -45.17 and a beta of 1.68. The business’s 50-day moving average is $4.65 and its 200-day moving average is $4.28.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The company had revenue of $150.86 million for the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in ORGO. First Light Asset Management LLC lifted its position in Organogenesis by 10.6% in the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock valued at $31,641,000 after buying an additional 720,748 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Organogenesis by 69.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock valued at $20,488,000 after purchasing an additional 1,997,038 shares in the last quarter. Vanguard Group Inc. lifted its stake in Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after acquiring an additional 841,618 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Organogenesis by 3.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock worth $8,862,000 after acquiring an additional 91,118 shares in the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in Organogenesis during the first quarter worth approximately $7,756,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ORGO shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research note on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, BTIG Research boosted their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Organogenesis has a consensus rating of “Hold” and an average target price of $8.00.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.